Mexico Neurologist Reports Decrease in Seizures in 60% of Cases, Crises Completely Controlled in 16%, and 51% of Patients Improved in a ‘Moderately to Important Way’
The following information is presented for educational purposes only. Medical Marijuana Inc. provides this information to provide an understanding of the potential applications of cannabinoids. Links to third party websites do not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred.
San Diego, CA – Sept, 30 2016 – Renowned Mexico physician Dr. Carlos G. Aguirre Velazquez today announced results of a new survey he conducted on children with refractory epilepsy, which found that out of 53 cases of children who were treated with cannabidiol (CBD) hemp oil, 60 percent showed a reduction in seizures.
The product most commonly used in the survey was the only current legal option in Mexico, Medical Marijuana, Inc. (OTC: MJNA)’s Real Scientific Hemp Oil-X™ (RSHO-X™), developed by HempMeds, the first company in Mexico with a COFEPRIS approval to import cannabis products.
The study, conducted by Professor of Pediatric Neurology at the Monterrey Institute of Techhas’ School of Medicine Dr. Velazquez, also reported that in seizure crises treated with CBD hemp oil, 16 percent were completely controlled, and 51 percent improved in either a moderately to an important way.
“This is such exciting news for our company and we are honored and humbled to witness this new work performed by D. Velazquez,” said Medical Marijuana, Inc.’s Chief Executive Officer Dr. Stuart Titus. “We are proud to be the first company with CBD products approved by the Mexico government, and thrilled to see the results that our products are producing for the quality of life for families that otherwise had no options.”
The survey was submitted to parents of the “Por Grace Foundation” Facebook Group, chaired by Raul Elizalde, father of the first patient treated with cannabis products in Mexico. The participation was voluntary and the criteria were: 1) a diagnosis of refractory epilepsy such as Lennox-Gastaut Syndrome, Dravet, Doose or other causes, and 2) the current use of medicinal cannabis (pure CBD or combined in different presentations).
Results from the study will be presented to other doctors across Mexico on September 30 as part of an ongoing effort inside the country to inform health professionals on the therapeutic uses of cannabis.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]